Summit Therapeutics plc Award Of Share Options
2019年12月24日 - 4:01PM
ＲＮＳを含む英国規制内ニュース （英語）
TIDMSUMM
Summit Therapeutics plc
('Summit' or the 'Company')
Award of Share Options
Oxford, UK, and Cambridge, MA, US, 24 December 2019 -- Summit
Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), a leader in new mechanism
antibiotic innovation, announces a grant of options over new ordinary
shares of one penny nominal value ('Ordinary Shares') on 23 December
2019 to Mr Manmeet Soni, Dr Elaine Stracker and Dr Ventzislav Stefanov.
The Company has also made a grant of share options to certain Company
employees in line with the Company's Long Term Incentive Plan.
Share Option Award to Prospective Non-Executive Directors
Mr Soni, Dr Stracker and Dr Stefanov will join the Board as
non-executive directors effective upon the close of the subscription and
placing to raise approximately $50 million (the "Fundraising") that was
announced by the Company on 6 December 2019. Following a general meeting
of shareholders where all resolutions connected to the Fundraising were
duly approved, the Fundraising is expected to close at 8.00 am GMT on 24
December 2019. Details of the grant of share options is as follows:
Number of Total % of
Number of outstanding number of enlarged
share share ordinary issued
options options shares Total number of ordinary shares upon the close of share
awarded held held the Fundraising capital
----------- --------- ----------- ---------- ------------------------------------------------- --------
Manmeet
Soni 1,000,000 1,000,000 Nil Nil Nil
----------- --------- ----------- ---------- ------------------------------------------------- --------
Elaine
Stracker 1,000,000 1,000,000 Nil Nil Nil
----------- --------- ----------- ---------- ------------------------------------------------- --------
Ventzislav
Stefanov 1,000,000 1,000,000 74,500 74,500 0.02%
----------- --------- ----------- ---------- ------------------------------------------------- --------
Robert
Duggan Nil Nil 78,288,205 244,445,255 72.78%
----------- --------- ----------- ---------- ------------------------------------------------- --------
All options awarded to Mr Soni, Dr Stracker and Dr Stefanov have an
exercise price of 21 pence per ordinary share, representing the
mid-market closing price on 20 December 2019. The share options will
vest in four equal tranches on the first, second, third and fourth
anniversaries of the date of the share option grant and will vest in
full on 23 December 2023, or sooner on the happening of certain
corporate events reflecting the achievement of the Company's long-term
objectives.
Employee Share Option Award
The Company has also granted options over 850,000 Ordinary Shares to
employees who have recently joined the Company. These options have an
exercise price of 21 pence per share. They will vest in nine equal
tranches on a quarterly basis from 23 December 2020 and will vest in
full on 23 December 2022, or sooner on the happening of certain
corporate events reflecting the achievement of the Company's long-term
objectives.
The exercise price of 21 SHYpence per share for the above option grants
was the mid-market closing price of the Ordinary Shares on AIM on 20
December 2019.
The maximum number of outstanding share options following the grants
referred to above is 23,399,465.
This announcement contains inside information for the purposes of
Article 7 of EU Regulation 596/2014. The person responsible for
arranging for the release of this announcement on behalf of the Company
is Richard Pye, Vice President, Investor Relations and Corporate
Affairs.
About Summit Therapeutics
Summit Therapeutics is a leader in antibiotic innovation. Our new
mechanism antibiotics are designed to become the new standards of care
for the benefit of patients, and create value for payors and healthcare
providers. We are currently developing new mechanism antibiotics for C.
difficile infection and gonorrhoea and are using our proprietary Discuva
Platform to expand our pipeline. For more information, visit
www.summitplc.com and follow us on Twitter @summitplc.
Contacts
Summit
Glyn Edwards / Richard Pye (UK office) Tel: 44 (0)1235 443 951
Michelle Avery (US office) +1 617 225 4455
Cairn Financial Advisers LLP (Nominated Adviser) Tel: +44 (0)20 7213 0880
Liam Murray / Tony Rawlinson
1 Details of the persons discharging managerial responsibilities/person
closely associated
--------------------------------------------------------------------------------------
a) Name
1. Manmeet Soni
2. Elaine Stracker
3. Ventzislav Stefanov
---------------------- --------------------------------------------------------------
2 Reason for the notification
--------------------------------------------------------------------------------------
a) Position / status (i)-(iii) Non-Executive Directors
(expected to be effective from 24 December 2019)
---------------------- --------------------------------------------------------------
b) Initial notification / Initial notification
Amendment
---------------------- --------------------------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
--------------------------------------------------------------------------------------
a) Name Summit Therapeutics plc
---------------------- --------------------------------------------------------------
b) LEI 213800NRW8AOMYMTBD89
---------------------- --------------------------------------------------------------
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place
where transactions have been conducted
--------------------------------------------------------------------------------------
a) Description of the Ordinary shares of 1 penny each
financial instrument,
type of instrument
Identification code GB00BN40HZ01
---------------------- --------------------------------------------------------------
b) Nature of the Grant of share options
transactions
---------------------- --------------------------------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
---------------------- ----------------------------------------- ---------------
(i)-(iii) 21.0 per share (exercise price) 1. 1,000,000
2. 1,000,000
3. 1,000,000
---------------------- ----------------------------------------- ---------------
d) Aggregated information
- Aggregated volume 3,000,000 ordinary shares
- Price 21.0 pence per share (exercise price)
---------------------- --------------------------------------------------------------
e) Date of the 23 December 2019
transactions
---------------------- --------------------------------------------------------------
f) Place of the Outside a trading venue
transactions
---------------------- --------------------------------------------------------------
-END-
(END) Dow Jones Newswires
December 24, 2019 02:01 ET (07:01 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Summit Therapeutics (LSE:SUMM)
過去 株価チャート
から 12 2024 まで 1 2025
Summit Therapeutics (LSE:SUMM)
過去 株価チャート
から 1 2024 まで 1 2025
